Belgium · Delayed Price · Currency is EUR Agfa-Gevaert NV Earnings Call Transcripts
Fiscal Year 2025
-
Q4 delivered record EBITDA and strong cash flow, offsetting a challenging year marked by Radiology decline and currency headwinds. HealthCare IT cloud transition accelerated, DPS faced setbacks, and restructuring costs will pressure 2026 cash flow, but profitability is expected to improve.
-
Q3 saw a sharp decline in medical film and a rapid shift to cloud in HealthCare IT, impacting short-term results but driving strong order intake. Cost-cutting and restructuring are being accelerated, with positive cash flow and improved net results year-over-year.
-
H1 2025 saw strong HealthCare IT growth and improved cash flow, but rapid decline in the medical film market and subdued digital printing and green hydrogen segments weighed on EBITDA. A EUR38 million Agfa Photo gain boosted net results, and further restructuring is underway.
-
Q1 2025 saw stable results with strong growth in healthcare IT offsetting declines in film and radiology, especially in China. The outlook for healthcare IT is upgraded, while DPC and ZIRFON face subdued growth due to market delays. Cost-saving measures and innovation support future performance.
Fiscal Year 2024
-
Record 2024 results driven by HealthCare IT, DPS, and ZIRFON, offsetting film decline. Transformation program underway, strong order intake, and growth engines expected to continue momentum in 2025, with cautious guidance due to subscription model transition.
-
DPC delivered strong double-digit growth, becoming the main profit driver, while Healthcare IT's rapid cloud transition boosted order intake but delayed revenue recognition. Radiology faced accelerated film market decline, prompting a major restructuring program.
-
Q2 saw strong order intake in Healthcare IT, robust DPC and ZIRFON growth, and a positive net profit, offset by continued radiology weakness. A €50 million productivity program was launched, and working capital is expected to normalize by year-end.